TherapeuticsMD (NASDAQ: TXMD) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its rivals? We will compare TherapeuticsMD to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.


This table compares TherapeuticsMD and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TherapeuticsMD -485.71% -74.25% -66.61%
TherapeuticsMD Competitors -540.60% -41.61% -24.68%

Volatility and Risk

TherapeuticsMD has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s rivals have a beta of 0.88, meaning that their average share price is 12% less volatile than the S&P 500.

Valuation and Earnings

This table compares TherapeuticsMD and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
TherapeuticsMD $18.26 million -$88.99 million -10.87
TherapeuticsMD Competitors $2.40 billion $905.93 million -0.53

TherapeuticsMD’s rivals have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for TherapeuticsMD and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD 0 1 8 0 2.89
TherapeuticsMD Competitors 66 309 958 27 2.70

TherapeuticsMD currently has a consensus target price of $14.88, suggesting a potential upside of 197.50%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.81%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, analysts plainly believe TherapeuticsMD is more favorable than its rivals.

Insider and Institutional Ownership

71.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 23.9% of TherapeuticsMD shares are owned by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


TherapeuticsMD beats its rivals on 7 of the 12 factors compared.

About TherapeuticsMD

TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with's FREE daily email newsletter.